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Neural tube defects (NTDs) are common, severe congenital malformations whose causation involves multiple
genes and environmental factors. Although more than 200 genes are known to cause NTDs in mice, there has
been rather limited progress in delineating the molecular basis underlying most human NTDs. Numerous
genetic studies have been carried out to investigate candidate genes in cohorts of patients, with particular
reference to those that participate in folate one-carbon metabolism. Although the homocysteine remethyla-
tion gene MTHFR has emerged as a risk factor in some human populations, few other consistent ﬁndings
have resulted from this approach. Similarly, attention focused on the human homologues of mouse NTD
genes has contributed only limited positive ﬁndings to date, although an emerging association between
genes of the non-canonical Wnt (planar cell polarity) pathway and NTDs provides candidates for future
studies. Priorities for the next phase of this research include: (i) larger studies that are sufﬁciently powered
to detect signiﬁcant associations with relatively minor risk factors; (ii) analysis of multiple candidate genes in
groups of well-genotyped individuals to detect possible gene–gene interactions; (iii) use of high throughput
genomic technology to evaluate the role of copy number variants and to detect ‘private’ and regulatory
mutations, neither of which have been studied to date; (iv) detailed analysis of patient samples stratiﬁed
by phenotype to enable, for example, hypothesis-driven testing of candidates genes in groups of NTDs
with speciﬁc defects of folate metabolism, or in groups of fetuses with well-deﬁned phenotypes such as
craniorachischisis.
INTRODUCTION
Congenital malformations are the leading cause of infant mor-
tality in developed countries and a major cause of health pro-
blems in surviving children. Neural tube defects (NTDs) are a
common group of central nervous system anomalies affecting
0.5–2 per 1000 pregnancies worldwide. NTDs arise when the
neural tube, the embryonic precursor of the brain and spinal
cord, fails to close during neurulation. The cranial region
(anencephaly) or the low spine (open spina biﬁda; myelome-
ningocele) are most commonly affected although, in the
severe NTD craniorachischisis, almost the entire neural tube
remains open, from midbrain to low spine.
Most individuals who survive with NTDs (particularly mye-
lomeningocele) have a multiple system handicap and a limited
life expectancy. However, despite the high prevalence and
traumatic consequences for affected individuals and their
families, the causes of NTD are poorly understood. Identiﬁ-
cation of causative factors is confounded by the fact that the
majority of these malformations appear to result from a
combination of genetic and environmental factors. A strong
genetic component is indicated by the high recurrence risk
for siblings of affected individuals (1,2). Syndromic cases of
NTD also exist, often associated with chromosomal
anomalies, but these represent ,10% of all defects (1,3–5).
The majority of NTDs are sporadic, with recurrence ﬁtting a
multifactorial polygenic or oligogenic pattern, rather than
models on the basis of single gene dominant or recessives,
with reduced penetrance (2).
GENETIC ANALYSIS OF HUMAN NTDS
Positional cloning strategies have been hampered by the
paucity of large families with multiple affected members.
Nevertheless, genome-wide studies using collections of
smaller multiplex families have implicated chromosomes 2,
7 and 10 as harbouring candidate risk loci for spina biﬁda
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doi:10.1093/hmg/ddp347(6–8). Although the causative genes are yet to be identiﬁed,
these studies may result in identiﬁcation of candidate
sequences that can be evaluated in larger populations. An
alternative approach exploits the association of NTDs with
chromosomal anomalies such as trisomies 13 and 18 (9),
suggesting that gene-dosage can affect neural tube closure.
Rearrangements involving deletions, duplications or balanced
translocations are likely to be most informative, with ﬁne
mapping of chromosomal breakpoints enabling identiﬁcation
of speciﬁc loci (10).
In some studies, direct mutation screening of candidate
genes has been carried out in cohorts of patients (11), but
the vast majority involve statistical association analysis of
sequence variants in or near candidate genes. Most work has
involved case–control analysis, comparing the frequency of
‘risk’ alleles in affected individuals and/or mothers with a
matched unaffected cohort. More sophisticated studies have
used the transmission disequilibrium test (TDT) in family
trios (mother, father and affected child), which is less depen-
dent on population structure. In the remainder of this article,
we review the main candidate gene studies which have
arisen primarily from analysis of folate metabolic pathways
and mouse models of NTDs. Boyles et al. (11) published a
comprehensive review of this ﬁeld up to 2004, and an
updated candidate gene list is presented in Table 1.
CANDIDATE GENES FROM FOLATE METABOLISM
Epidemiological studies provide an opportunity to identify risk
factors for NTDs, such as dietary or teratogenic agents, to
which susceptibility may be modiﬁed by genetic predisposi-
tion (12–14). Among environmental factors, folate status
plays a key role in determining NTD risk (15,16). Maternal
supplementation with folic acid during pregnancy reduces
NTD frequency (17,18) whereas reduced serum folate and/or
elevated homocysteine (an inverse indicator of folate status)
are observed in some mothers of NTD fetuses, and are con-
sidered risk factors for NTDs (19–21). However, NTDs are
not simply a condition of folate deﬁciency: maternal folate
levels in most human NTD-affected pregnancies are in the
‘normal’ range (22), suggesting that low folate status may
increase susceptibility but is not directly causative. Similarly,
in mice dietary folate deﬁciency can cause signiﬁcant embryo-
nic growth retardation but does not cause NTDs (16,23,24).
Hence, sub-optimal folate status may pre-dispose to NTDs
in combination with additional factors, either environmental
or genetic.
The intricate interplay and cross-regulation between
elements of one-carbon (folate) metabolism (Fig. 1) compli-
cates the teasing out of events that impinge on neural tube
closure. In mice, key cellular functions in the developing
embryo include methylation reactions and biosynthesis of
nucleotides that support rapid cellular proliferation (2,25).
Cranial NTDs arise when the methylation cycle is inhibited
(26,27), and in null embryos for DNA methyltransferase 3B
(28). In contrast, exogenous homocysteine does not cause
NTDs (29–31), even in genetically predisposed splotch
embryos (24) and may be an indicator of impaired folate or
methylation cycle activity.
If folate status interacts with genetic factors in the causation
of NTDs, this could involve either folate-related or
folate-independent genes. To date, most emphasis has been
placed on the evaluation of folate-related genes as NTD can-
didates (32,33) (Table 1). Further support comes from analysis
of primary cell lines obtained from NTD fetuses, which indi-
cates that a genetically-determined abnormality of folate
metabolism is present, in at least a proportion of cases (34).
However, identifying speciﬁc NTD-predisposing genetic
lesions has proven far from straight forward. Although a
number of variants have been widely studied, inconsistent
results between different cohorts and populations (Table 1)
indicate that very few, if any, have a major causative effect.
Below, we sub-divide the candidate folate-related genes into
three functional categories.
Methylation related genes
Among folate-related genes, 5,10-methylene tetrahydrofolate
reductase (MTHFR) has been the principal focus of attention,
following reports that the 677C.T (A222V; rs1801133) poly-
morphism is associated with increased risk of NTDs in Dutch
and Irish populations (35–37). Other populations show no
association (38,39) or even a protective effect (40,41)
(Table 1). A meta-analysis, including genotype data from 27
studies up to 2004, suggests that the 677TT genotype
confers an overall 1.9 times increase in NTD risk (Odds
ratio: 1.9; 95% conﬁdence interval: 1.6–2.2) (15). A more
recent meta analysis (42) found a positive association only
in non-latin groups, principally the Irish population.
The action of MTHFR generates 5-methylTHF for remethy-
lation of homocysteine, at the expense of other folates required
for purine and pyrimidine biosynthesis (Fig. 1). The A222V
variant protein has reduced function and is associated with
elevated plasma homocysteine (36). Nullizygosity for
MTHFR in mice also results in elevated homocysteine and
diminished DNA methylation (43), although NTDs are not
observed under either normal or folate-deﬁcient conditions.
Moreover, MTHFR nullizygosity does not exacerbate the
folate-responsive splotch mutation (43–45). These data
suggest that in populations where MTHFR is a risk factor,
additional interacting factors are likely to be present.
The link between reduced methylation/elevated homocys-
teine and NTDs has prompted analysis of variants in other
genes that could inﬂuence the methylation cycle through
remethylation (MTR, MTRR, BHMT and BHMT2) or trans-
sulfuration (CBS) of homocysteine (11) (Table 1). In
general, mildly elevated risks have been identiﬁed in some
studies but rarely replicated. MTRR (methionine synthase
reductase) functions to maintain activity of MTR (methion-
ine synthase), and a variant form (I22M, encoded by
66A.G) was reported as an NTD case and maternal risk
factor in some studies, but not others (Table 1). Mouse
studies do not support a role for these genes in NTDs: tar-
geted deletion of Mtr is embryonic lethal prior to neurulation
stages and heterozygotes do not show NTDs (46). Similarly,
reduced activity of Mtrr and loss of cbs function do not
cause NTDs, although elevated plasma homocysteine is
observed (47,48).
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Human gene Type of candidate Reference Population
studied
Sample size Type of study Summary of results/conclusion
AHCY (S-adenosylhomocysteine hydrolase) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
ALDH1L1 (Aldehyde dehydrogenase 1, member
L1)
One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study Nominally signiﬁcant association
with Asp793Glu variant
a
ALDH1A2 (Retinaldehyde dehydrogenase Type 2,
RALDH2)
Retinol metabolism (104) USA 318 SB families Family based
association study
One polymorphism associated with
increased SB risk (tentative
association for two others)
AMD1 (Adenosyl methionine decarboxylase 1) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
APE1 (apurinic endonuclease1) DNA repair (112) Mixed USA 380 SB cases, 350 controls Case–control study Suggestion of reduced risk for
Asp148Glu variant
BHMT (betaine-homocysteine methyltransferase) One carbon metabolism (113) Mixed USA 252 SB cases, 337 controls Case–control study No association for Arg239Gln
polymorphism
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study Modest increase in SB risk
associated with 1 SNP (of eight
tested)
BHMT2 (betaine-homocysteine methyltransferase
2)
One carbon metabolism (56) Dutch 180 SB patients, 190 controls Association study No association detected
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association for 7 SNPs tested
BRCA1 (breast cancer 1) NTDs in mouse mutant (114) USA 268 SB patients and parents Family based
association study
(TDT)
Association with SB for two
microsatellite markers and
A4956G SNP. Proposed
polymorphisms affect level of
lesion, not causative
CAT (catalase) Oxidative stress (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
CBS (cystathionine beta-synthase) Folate metabolism (116) UK 207 NTD cases (200 mothers,
93 fathers). 601 controls,
542 control mothers
Case–control study No association for 844ins68
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control (9
SNPs)
Modest increase in SB risk
associated with 2 SNPs
CFL1 (n-coﬁlin) NTDs in mouse mutant (117) Mixed USA 246 SB cases, 336 controls Case–control SNPs Mildly elevated risk of NTDs in
non-Hispanic whites
CHKA (choline kinase A) One carbon metabolism (118) Mixed USA 103 SB cases, 338 controls Case–control study Possible association with reduced
SB risk for 1 of 2 SNPs studied
CITED2 NTDs in mouse mutant (119) Mixed USA 64 SB cases, 72 controls Mutation screen and
case–control
No mutations. No association of
three 50-UTR SNPs with risk
COQ3 (Coenzyme Q3 homolog,
methyltransferase)
Methylation (56) Dutch 180 SB patients, 190 controls Case–control study No association
CRABPI (cellular retinoic acid binding protein I) Retinol metabolism (104) USA 230 SB cases, 318 SB
families
Mutation screen and
family based
association study
No mutations. No association (3
SNPs tested)
CRABPII (cellular retinoic acid binding protein II) Retinol metabolism (104) USA 230 SB cases Mutation screen No mutations
CTH (Cystathionase) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
CUBN (cubulin) Endocytosis (folate
transport)
(56) Dutch 179 SB patients, 190 controls Case–control study GG genotype for rs1907362
signiﬁcantly associated with
reduced SB risk
CYP26A1 (cytochrome P450) Retinol metabolism (104) USA 230 SB cases Mutation screen No mutations
CYP26B1 (cytochrome P450) Retinol metabolism (104) USA 230 SB cases, 318 SB
families
Mutation screen and
Family based
association study
No mutations. No association (5
SNPs tested)
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5Table 1. Continued
Human gene Type of candidate Reference Population
studied
Sample size Type of study Summary of results/conclusion
DHFR (Dihydrofolate reductase) Folate metabolism (120) Mixed USA 61 SB cases and parents
(multi-affected families)
and 219 controls
Case–control study of
19-bp intron-1
deletion
The del/del genotype was more
frequent in mothers of SB cases,
compared with controls. No
association in fathers or patients
(121) Irish 283 cases (and 280 mothers,
279 fathers) and 256
controls. SB (95%) or
encephalocele (5%)
Case–control study.
19-bp deletion and
two 30-UTR
variants.
19-bp Intron deletion shows
protective effect. May increase
mRNA levels
(122) Dutch 109 patients, 121 mothers
(SB). 234 paediatric
controls, 292 control
women
Case–control study.
19-bp deletion and
9-bp repeat in
50-UTR
19-bp Intron deletion not associated
with NTDs. No effect on
expression
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association for 9 SNPs tested.
Intron deletion not tested
(41) Mixed UK 126 SB (open); 103 SB
(closed); 49 anencephalic;
192 controls
Case–control study No association
FOLR1 (Folate receptor 1) Folate transport (56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association for 3 SNPs tested
FOLR2 (Folate receptor 2) Folate transport (56) Dutch 180 SB patients, 190 controls Association study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association for 3 SNPs tested
FOLR3 (Folate receptor 3) Folate transport (56) Dutch 180 SB patients, 190 controls Case–control study No association
FPGS (Folylpolyglutamate synthase) Cellular folate retention (56) Dutch 180 SB patients, 190 controls Case–control study No association
FTCD (Formininotransferase cyclodeaminase One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
GAMT (Guanidinoacetate N-methyl transferase) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
GAPD (glyceraldehyde 3 phosphate
dehydrogenase)
Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
GART (Phosphoribosylglycinamide
formyltransferase, phosphoribosyl glycinamide
synthetase, phosphoribosyl aminoimidazole
synthetase)
Purine biosynthesis (one
carbon metabolism)
(56) Dutch 180 SB patients, 190 controls Association study No association
GCPII (glutamate carboxypeptidase), FOLH1
(Folate hydrolase)
Folate metabolism (116) UK 208 NTD cases (200 mothers,
92 fathers). 600 child, 531
mother controls
Case–control study No association for 1561C.T
(56) Dutch 180 SB patients, 190 controls Case–control study No association
GGH (Gamma-glutamyl hydrolase) Folate metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
GLUT1 (glucose transporter 1) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study Pro196 silent SNP associated with
risk in TDT test
GLUT4 (glucose transporter 4) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
HK1 (hexokinase 1) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study Lys481 SNP variant associated with
risk in TDT test
HK2 (hexokinase 2) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
ICMT (Isoprenylcysteine carboxyl
methyltransferase)
Protein methylation (56) Dutch 180 SB patients, 190 controls Association study No association
INS (insulin) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
INSR (insulin receptor) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
LEP (leptin) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study Arg109Lys variant associated with
risk in TDT test
LEPR (leptin receptor) Glucose metabolism (115) Mixed USA 507 SB cases, 185 controls Case–control study Arg109Lys variant associated with
risk in TDT test
MAT1A (Methionine adenosyltransferase I, alpha) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
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2MAT2A (Methionine adenosyltransferase II, alpha) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
MGMT (O-6-Methylguanine DNA
methyltransferase)
One carbon metabolism
DNA methylation
(56) Dutch 180 SB patients, 190 controls Case–control study No association
MTHFD1 (methylenetetrahydrofolate
dehydrogenase/
methylenetetrahydrofolate-cyclohydrolase/
formyltetrahydrofolate synthetase)
Folate metabolism (50) Irish 176 NTD cases (Mostly SB,
few encephalocele). 245
mothers, 127 fathers (also
includes parents of
anencephalic cases). 770
controls
Case–control to
evaluate
Arg653Gln
(1958G.A;
dbSNP rs 1801133)
polymorphism
Maternal AA genotype confers
increased risk to offspring
(51) Italian 142 NTD cases (open and
closed SB) (125 mothers,
108 fathers). 523 controls.
Case–control study
and family based
association study
(TDT) for
1958G.A
Mildly increased risk for AA and
GA genotypes in cases (and
mothers). TDT shows excess
transmission of A allele to cases
(52) Dutch 103 SB cases, 113 mothers,
98 fathers. 460 controls.
Case–control and
TDT for 1958G.A
No association
(54) Irish 509 cases (with 485 mothers
and 439 fathers)—mostly
open SB. 966 controls.
Case–control study
for SNP
rs1076991C.T
Promoter variant not independent
risk factor. Case and maternal
risk factor when combined with
Arg653Gln variant
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control (10
SNPs)
Increased SB risk for one SNP,
decreased risk for three others
(41) Mixed UK 126 SB (open); 103 SB
(closed); 49 anencephalic;
192 controls
Case–control study No association
MTHFD2 Folate metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association for 8 SNPs tested
MTHFR (5,10-methylenetetrahydrofolate
reductase)
Folate metabolism (116) UK 200 NTD cases (186 mothers,
92 fathers). 578 child, 512
mother controls
Case–control study Mildly elevated risk for 677C.T.
No association for 1298A.C
(123) Polish 20 NTD cases, 262 controls. Case–control for
C677T and
A1298C
No association
(124) Irish 471 cases (451 SB, 20
encephalocele). Triads
comprise .1300 samples.
922 controls.
Mutation screen.
Case–control and
TDT for 116C.T
(P39P) and
1793G.A
(R594Q)
Possible association with SB for
variants tested. Unlikely to be
independent risk factors
(association likely due to linkage
disequilibrium with 677C.T)
(125) Mixed USA 350 cases, 328 mothers, 245
fathers, 167 siblings
Family-based
association study
No association for 677C.T
(126) Italian 15 cases (open SB), 18
fathers, 60 mothers. 43
control children and 100
control adults
Case–control screen
for C677T and
A1298C
T allele more frequent in cases than
controls. A1298C not different
between groups
(127) Mexican 118 NTD case mothers (all
anencephalic), 112 control
mothers
Case–control study
for C677T and
A1298C
Maternal TT confers higher risk
than CC for anencephaly.
A1298C not associated with
NTDs
(128) Indian 83 mothers of NTD cases. 60
controls
Case–control for
C677T and
A1298C
677T more frequent in mothers of
cases than in controls (only for
lower defects). No difference in
A1298C frequency
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7Table 1. Continued
Human gene Type of candidate Reference Population
studied
Sample size Type of study Summary of results/conclusion
(129) Mexican
(Yucatan)
108 cases (97 SB, 4
anencephalic, 7
encephalocele), with 147
parents. 120 controls
Case–control, screen
for A1298C
No association
(130) French 77 NTD mothers. 61 controls Case–control study No association for 677C.T.
Reduced risk for 1298A.C
allele
(131) Chinese 38 mothers of NTD cases. 80
controls
Case–control to
evaluate 677C.T
TT genotype less frequent in case
mothers (but small numbers)
(56) Dutch 180 SB patients, 190 controls Case–control study No association for 677C.To r
1298A.C
(103) Mixed USA 259 SB cases, 359 controls Case–control (13
SNPs)
Increased risk, OR2.0, of SB
associated with 677C.T
(41) Mixed UK 126 SB (open); 103 SB
(closed); 49 anencephalic;
192 controls
Case–control for
C677T and
A1298C
Slight protective effect for open SB
of 677TT genotype
MTHFS (5,10-methylenetetrahydrofolate
synthetase)
Folate metabolism (56) Dutch 180 SB patients, 190 controls Case–control study No association
MTR (methionine synthase) One carbon metabolism
(homocysteine
remethylation)
(105) Hispanic
USA
43 NTD cases, 122 mothers.
124 control infants and 127
mothers
Case–control study
for 2756A.G
Not independent risk factor. May be
associated with NTDs in
combination with MTRR
66A.G
(130) French 77 NTD mothers. 61 controls Case–control study No association for 66A.G
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association with SB for 21 SNPs
tested (including 2756A.G)
(41) Mixed UK 126 SB (open); 103 SB
(closed); 49 anencephalic;
192 controls
Case–control study No association
MTRR (methionine synthase reductase) One carbon metabolism
(homocysteine
remethylation)
(105) Hispanic
USA
43 NTD cases, 122 mothers.
124 control infants and 127
mothers
Case–control study
for 66A.G (I22M)
G allele associated with increased
risk. Additional risk in
combination with MTR 2756G
allele
(116) UK 201 NTD cases (203 mothers,
88 fathers). 601 child, 532
mother controls
Case–control study Mildly reduced risk associated with
66A.G
(132) Irish 575 NTD families 95% SB).
487 controls.
Case–control and
family-based
analysis for three
variants
No association for 66A.G (I22M)
with SB risk (except possible
paternal effect). No association
for S175L or K350R
(133) Dutch 109 cases (open SB) and
parents. 234 control
children, 292 control
women.
Case–control screen
for 66A.G
In this study and meta-analysis
(including previous studies)
maternal GG is associated with
increased risk in offspring, but
GG in child not associated with
NTDs
(130) French 77 NTD mothers. 61 controls Case–control study Marginally increased risk
associated with 66G allele
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study Modest increase in SB risk for three
linked SNPs, but not 66A.G
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(closed); 49 anencephalic;
192 controls
Case–control study Marginal increased risk for
combined NTDs
MUT (methylmalonyl-CoA mutase) One carbon metabolism (134) Irish 279 NTD triads (mostly SB),
256 controls
Case–control and
family-based study
No association with NTDs for three
variants tested
NAT1 (N-acetyltransferase 1) Folate metabolism and
acetylation reactions
(135) Mixed USA 354 NTD families Family based
association study
1095C.A not associated with SB
risk (except in combination with
maternal smoking)
(136) Mixed USA 374 NTD families Family based
association study
Composite genotype (6 SNPs)
related to reduced function
associated with lower SB risk for
cases and mothers
NAT2 (N-acetyltransferase 2) (56) Dutch 180 SB patients, 190 controls Case–control study No association
NNMT (Nicotinamide N-methyltransferase) Methylation reactions (137) Mixed USA 252 SB cases, 335 controls Case–control study No association between NNMT
variants and SB risk
(56) Dutch 180 SB patients, 190 controls Association study No association
NCAM1 (neural cell adhesio ´n molecule1) Embryonic cell adhesion (138) USA 204 SB families Family based
association study
Risk of SB associated with intronic
SNP (of 11 tested) in ﬁrst 132
families, not in further 72
families
NOS1 (nitric oxide synthase 1) Possible effect on one
carbon metabolism
(56) Dutch 180 SB patients, 190 controls Case–control study No association for repeat
polymorphisms
NOS2 (nitric oxide synthase 2A) (56) Dutch 180 SB patients, 190 controls Case–control study No association for SNPs and repeat
polymorphism
NOS3 (nitric oxide synthase 3 endothelial) (139) Mixed US 301 families with SB Family based
association study
No association by TDT analysis.
Maternal 894G.T associated
with SB risk by log-linear
modelling
(140) Dutch 109 SB cases, 121 mothers,
103 fathers. 500 controls
Case–control and
TDT
894G.T not independent risk
factor. Possible risk interaction
with MTHFR 677TT
(56) Dutch 180 SB patients, 190 controls Case–control study No association detected for SNPs
and repeat polymorphism
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association
hOGG1 (8-hydroxyguanine DNA-glycosylase1) DNA repair (112) Mixed USA 380 SB cases, 350 controls Case–control study No association
PAX3 NTDs in mouse mutant (70) Mixed USA 74 SB cases, 87 controls Mutation screen and
case–control study
rs16863657 and related haplotype
associated with increased SB risk
PCMT1 (l-isoaspartate O-methyltransferase) Methylation reactions (141) Mixed USA 152 SB cases, 423 controls Case–control study of
Ile120Val
Val/Val genotype associated with
possible reduction in SB risk
(56) Dutch 180 SB patients, 190 controls Case–control study No association for Ile120Val
PDGFRA (Platelet derived growth factor receptor
alpha)
NTDs in Patch mouse
mutant
(142) US Hispanic 43 NTD cases, 122 NTD
mothers. 124 control
infants, 127 control
mothers
Case–control study
for promoter
haplotypes
P1 promoter haplotypes with lower
activity may be associated with
maternal risk. Case numbers too
small for conclusion
(143) Mixed USA 407 parent-child triads (SB).
164 controls
Case–control and
family based
association (TDT)
No association for P1 promoter
haplotypes
(108) Dutch 88 SB cases, 56 SB mothers.
74 controls, 72 control
mothers
Evaluated H1 and H2
promoter
haplotypes
H1 promoter may be more frequent
in cases than controls.
Suggestion that BMI, glucose
and inositol differentially
interact with H1/H2
PEMT (Phosphatidylethanolamine
N-methyltransferase)
One carbon and choline
metabolism
(144) Mixed USA 360 SB cases, 595 controls Case–control study No association with SB for two
non-synonymous SNPs
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Human gene Type of candidate Reference Population
studied
Sample size Type of study Summary of results/conclusion
PRKACA, PRKACB (cAMP-dependent protein
kinase A catalytic subunits)
NTDs in mouse mutants (145) Mixed USA 207 SB cases, 209 controls Mutation screen and
case–control study
No mutation. No association
PRMT1 (Protein arginine methyltransferase 1) Methylation reactions (56) Dutch 180 SB patients, 190 controls Case–control study No association
PRMT2 (Protein arginine methyltransferase 2) Methylation reactions (56) Dutch 180 SB patients, 190 controls Case–control study No association
PYCT1A (CTP:phosphocholine cytidyltransferase) One carbon metabolism (118) Mixed USA 103 SB cases, 338 controls Case–control study Weak association with SB risk for 1
of 2 SNPs studied
RNMT (RNA (guanine-7-) methyltransferase) Methylation reactions (56) Dutch 180 SB patients, 190 controls Case–control study No association
SARDH (Sarcosine dehydrogenase) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study Nominally signiﬁcant association
with two synonymous SNPs
a
SHMT (Serine hydroxyl methyltransferase I) One carbon metabolism (146) UK 97 NTD mothers, 190
controls
Case–control study 1420C.T associated with
protective maternal effect
(56) Dutch 180 SB patients, 190 controls Case–control study No association for Leu474Phe
SLCA19A1, RFC-1 (reduced folate carrier), Folate transport (116) UK 206 NTD cases (186 mothers,
92 fathers). 578 child, 512
mother controls
Case–control study No association for 80G.A (H27R)
(125) Mixed USA 350 cases, 328 mothers, 245
fathers, 167 siblings.
Family-based
association study
No association for 80G.A
(147) Irish 437 NTD families, 852
controls
Case–control and
family based
association
No association for 80G.A. 61-bp
polymorphism under-represented
in cases
(131) Chinese 38 mothers of cases. 80
controls
Case–control for
80G.A
Association of GG genotype with
risk of NTD offspring
(148) Chinese 104 NTD families, 100
control families
Case–control for
80G.A
Elevated risk for GG genotype of
cases or mother (if folic acid not
used)
(56) Dutch 180 SB patients, 190 controls Case–control study Nominally signiﬁcant association
for 80AA genotype and reduced
risk
a
(103) Mixed USA 259 SB cases, 359 controls Case–control study No association with risk of SB for 6
SNPs tested. 80G.A not tested
(41) Mixed UK 126 SB (open); 103 SB
(closed); 49 anencephalic;
192 controls
Case–control study No association
SOD2 (superoxide dismutase 2) Oxidative stress (115) Mixed USA 507 SB cases, 185 controls Case–control study No association
T (Brachyury) Axial development in
mouse
(149) Mixed USA 316 SB families Family-based
association study
TIVS7 T/C allele more frequent in
cases than expected
TCNII (transcobalamin II) One carbon metabolism (150) Irish 350 NTD families, 700
controls.
Case–control and
family based
association study
No association with SB risk for 6
SNPs
(130) French 77 NTD mothers. 61 controls Case–control study No association for 776C.G
(56) Dutch 180 SB patients, 190 controls Case–control study No association for Arg259Pro
TXN2 (thioredoxin2) NTDs (SB) in mouse
knockout
(151) Mixed USA 48 SB cases, 48 controls Case–control study A2 promoter allele associated with
risk of NTDs but small sample
size
TP53 (p53) NTDs in mouse mutant (152) Irish 549 NTD cases, 532 mothers,
481 fathers. 999 controls
Case–control and
family based
association studies
Two non-coding variants associated
with case NTD risk and two
variants with maternal risk (but
no multiple testing correction)
(115) Mixed USA 507 SB cases, 185 controls Case–control study No association
TRDMT1 (tRNA aspartic acid methyltransferase 1) One carbon metabolism (56) Dutch 180 SB patients, 190 controls Case–control study Nominally signiﬁcant association
for one SNP
a
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pyrimidine
biosynthesis
(110) Mixed USA 264 SB cases, 259 controls. Mutation screen and
case–control for
28-bp repeat in
50-UTR and 6-bp
deletion in 30-UTR
30-UTR polymorphism associated
with increased SB risk in
non-Hispanic white population.
Further increased risk with
50-UTR polymorphism
(153) UK 197 NTD cases, 194 mothers,
93 fathers. 179 control
infants, 177 control
mothers
Case–control study of
28-bp repeat
No association for TYMS
(56) Dutch 180 SB patients, 190 controls Case–control study No association
(103) Mixed USA 259 SB cases, 359 controls Case–control study Modest increase in SB risk for three
linked SNPs (of 5 tested)
UCP2 (uncoupling protein 2) Energy metabolism
Previous study
indicates association
with NTDs
(154) Irish 169 cases, 163 mothers, 167
fathers
Evaluated 866G/A,
A55V, 30-UTR
45-bp ins/del
UCP2 not associatedwith NTD risk.
Different frequency of risk allele
in control population compared
with previous study
VANGL1 (van gogh-like 1) PCP gene homologue;
Paralogue of
VANGL2
(95) Mixed UK
and USA
66 (21 craniorachischisis, 24
SB, 21 anencephalic) and
200 controls
Mutation screen No causative mutations. One
missense variant, present in
controls
(96) Italian and
French
144 (80 SB, 7
craniorachischisis, 22
closed spinal dysraphism,
35 caudal regression). 172
Italian and CEPH controls
Mutation screen Three missense mutations (two in
myelomeningocele, R274Q and
M328T; 1 in caudal regression,
V239I). V239I has functional
effect on interaction with Dvl
proteins
(97) Italian and
USA
673 cases (15 open cranial
dysraphisms, 456 SB, 202
closed spinal dysraphisms)
Mutation screen Ten missense variants in 13
individuals (absent in 1187–
1462 controls). Five in highly
conserved residues (two in
myelomeningocele, three in
closed spinal dysraphism/caudal
regression syndrome)
VANGL2 (van gogh-like 2) Mouse model:
Craniorachischisis in
loop-tail mice
(95) Mixed UK
and USA
66 (21 craniorachischisis, 24
SB, 21 anencephalic) and
200 controls
Mutation screen No causative mutations identiﬁed.
7 bp duplication in intron six in
one craniorachischisis
(96) Italian and
French
144 (80 SB, 7
craniorachischisis, 22
closed spinal dysraphism,
35 caudal regression) and
172 Italian and CEPH
controls
Mutation screen No coding mutations
XPD (DNA excision repair protein ERCC-2) DNA repair (112) Mixed USA 380 SB cases, 350 controls Case–control study Mildly elevated risk associated with
751Gln
XRCC1 (X-ray repair cross-complementing) DNA repair (112) Mixed USA 380 SB cases, 350 controls Case–control study No association
XRCC3 (X-ray repair cross-complementing) DNA repair (112) Mixed USA 380 SB cases, 350 controls Case–control study No association
ZIC1 Brain defects in mouse
mutant
(155) Dutch 117 NTDs (SB, Anencephaly,
Encephalocele), 364
controls
Mutation screen No mutations
ZIC2 NTDs in mouse mutant (155) Dutch 117 NTDs (SB, Anencephaly,
Encephalocele), 364
controls
Mutation screen;
case–control study
Alanine deletion in one patient.
Frequent polymorphism
(1059C.T) has no association
ZIC3 NTDs in mouse mutant (155) Dutch 117 NTDs (SB, Anencephaly,
Encephalocele), 364
controls
Mutation screen One silent variant (858G.A) in one
patient
aNominally signiﬁcant association which does not stand after correction for multiple testing. SB, deﬁned as spina biﬁda (myelomeningocele) in study criteria. For studies labelled NTDs,
populations were mixed (multiple types of NTDs) or undeﬁned.
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MTHFD1 encodes the cytoplasmic trifunctional C1THF
synthase enzyme. A polymorphism (1958G.A; rs2236225)
which results in an R653Q substitution in the 10-formylTHF
synthetase domain was found to be both a maternal and
NTD case risk factor, in the Irish and Italian populations
(49–51), although not in the Dutch (51,52) or British (41).
The R653Q polymorphism causes reduced C1THF synthase
activity in cell lines, resulting in diminished purine biosyn-
thesis (53). A promoter polymorphism (rs1076991C.T) in
MTHFD1, that reduces transcriptional activity in vitro, was
also associated with NTD case and maternal risk, in combi-
nation with R653Q (54).
Folate transport
Another attractive group of candidate genes are those encod-
ing proteins required for transport, uptake and cellular reten-
tion of folates. This includes folate receptors FRa (Folr1 in
mice), FRb and FRg, RFC1 (reduced folate carrier), GCPII
(folyl-g-glutamate carboxypeptidase) and FPGS (folylpoly-
glutamate synthetase) (32,33). Increased risks associated
with variants in RFC1 and GCPII are not reproduced in
all studies (Table 1), although the recently identiﬁed
proton-coupled folate transporter PCFT (SLC46a1) is not
required for embryonic survival or neural tube closure in
mice (55), but has not yet been investigated in humans. A
recent case–control study revealed a possible association
with reduced risk of spina biﬁda for a polymorphism in
CUBN (Cubulin), which encodes a membrane-associated
multi-ligand endocytic receptor expressed in the neural
folds and yolk sac (56). Together, cubulin and its partner
protein megalin are involved in binding and endocytic
uptake of a large number of different proteins, several of
which could be important for neural tube closure, including
the intrinsic factor-cobalamin complex (IF-B12) and folate
binding protein (folate receptor) (57,58). Intriguingly, Cubn
was one of the most up-regulated genes in a microarray
analysis of Rfc1 null mouse embryos (59), which may
Figure 1. Summary of folate one-carbon metabolism showing the main pathways and reactions that have been subject to analysis in the context of NTDs. Blue
shading: proteins involved in processing of folates in the digestive tract, transport and cellular retention (by addition of glutamates). Yellow shading: the major
part of the cycle involving transfer of 1C groups between folate molecules, as required for purine and pyrimidine biosynthesis. Pink shading: reactions of the
methylation cycle. For clarity, mitochondrial reactions that include generation of formate and cleavage of glycine have been omitted. For explanation of abbrevi-
ations, see Table 1.
R122 Human Molecular Genetics, 2009, Vol. 18, Review Issue 2reﬂect a compensatory mechanism to enhance endocytic
folate uptake via Folr1. Hence, CUBN merits further atten-
tion as a potential risk factor, especially in conjunction
with RFC1.
In view of the apparent resilience of mouse neurulation to
speciﬁc genetic disturbance of the methylation cycle, analysis
of compound mutants with other folate-related or NTD sus-
ceptibility alleles would be of considerable interest. In our
analysis of NTD cell lines, impaired folate cycle activity did
not correlate with known variants in MTHFR, MTHFD1,
DHFR, GCPII, MTR, MTRR or RFC1 (34), encouraging the
view that currently unknown genetic inﬂuences on folate
metabolism remain to be identiﬁed in many NTD cases.
CANDIDATE GENES FROM THE MOUSE
The potential complexity of NTD genetics is illustrated by the
fact that 200 or more different mouse genes result in NTD
phenotypes either through naturally occurring, induced or tar-
geted mutations (2,25). Many of the NTD-causing mouse
mutations implicate speciﬁc signalling pathways such as non-
canonical Wnt signalling (see below), maintenance of the cell
cycle, regulation of the actin cytoskeleton, chromatin organiz-
ation or epigenetic modiﬁcations including methylation and
acetylation. Recently, NTDs were observed in mice null for
Mib2 (60), Smurf1/2 (61) and Hectd1 (62), which all encode
E3 ubiquitin ligases, suggesting a possible role in neurulation
for protein ubiquitination and targeted degradation. The
human homologues of some of these mouse NTD genes
have been examined in case–control association studies or
directly sequenced in mutation screens, although with very
few signiﬁcant ﬁndings to date (Table 1).
It is important to ask how appropriate are the mouse models
as paradigms for human NTDs? At the embryonic level, the
events of neurulation appear extremely similar between mice
and humans. For example, the initial fusion event, Closure
1, occurs at a closely similar stage and body axial level in
both species, as does initiation of closure in the forebrain
(Closure 3) and completion of spinal closure at the posterior
neuropore. One point of variation concerns de novo initiation
of closure at the forebrain/midbrain boundary (Closure 2 in
mice) which may be absent from human neurulation (63).
Hence, brain closure could be a rather simpler process in
humans than mice.
Another potential difference between mouse models and
human NTDs is that many gene-speciﬁc homozygous null
mouse embryos exhibit phenotypes additional to NTDs, such
as prenatally lethal heart defects. Such syndromic examples
do not appear particularly close models for human NTDs
which are primarily non-syndromic (64). On the other hand,
detailed analysis of a few of the mouse mutants suggests
that isolated NTDs can also result from the effect of hypo-
morphic alleles, combinations of heterozygous mutations,
genetic background effects and/or gene-environmental inter-
actions. This partial loss of function or multifactorial aetiolo-
gies may more closely resemble human NTDs. For example,
NTDs in splotch mice result from homozygosity for mutations
in Pax3 (23,65) but can also occur, or be exacerbated, as a
result of interaction with mutations in other genes including
neuroﬁbromin1 (66) and grainyhead-like-3 (67). Environ-
mental factors including folate deﬁciency and arsenic can
exacerbate NTDs in homozygous splotch mutants, or induce
NTDs in the usually unaffected heterozygotes (24,68).
Although association studies in humans have provided little
evidence to implicate PAX3 mutations in human NTDs
(69,70), the possible contribution of gene–gene and gene–
environment interactions indicates that larger scale studies
may be needed before a role for PAX3 in human NTDs can
be completely ruled out.
The curly tail mouse also exhibits features typical of the
multifactorial aetiology of human NTDs (71). Spinal NTDs
are partially penetrant in homozygous ct/ct mutant embryos,
with the frequency of defects strongly affected by genetic
modiﬁers (72). The major ct gene is a hypomorphic allele of
Grhl3, whose knockouts display completely penetrant spina
biﬁda (73–75). The ct mutation appears to affect a regulatory
region, emphasising the need for consideration of possible
non-coding mutations in human NTDs. Moreover, there is a
strong effect of environmental factors, including a protective
effect of supplemental inositol (76). A key role for inositol
in neural tube closure is supported by the ﬁnding that inositol
deﬁciency in vitro causes NTDs (77), inositol may prevent
diabetes-associated NTDs (78) and the recent ﬁnding of
NTDs in embryos carrying a hypomorphic allele of inositol
1,3,4-trisphosphate 5/6-kinase (Itpk1), a key enzyme in inosi-
tol phosphate metabolism (79).
Planar cell polarity signalling and NTDs
A major advance in understanding the genetic basis of neuru-
lation has been the ﬁnding that initiation of closure at the
hindbrain-cervical boundary (Closure 1) requires non-
canonical Wnt signalling: the so-called planar cell polarity
(PCP) pathway (Fig. 2). PCP signalling was deﬁned originally
Figure 2. Diagrammatic representation of non-canonical Wnt signalling in a
mammalian cell. Black arrows indicate the signalling pathway necessary for
establishment of planar cell polarity (PCP). Known biochemical interactions
are indicated by blue arrows and genetic interactions are shown by red
arrows. Ankdr6 is the mammalian homologue of Diego which in Drosophila
interacts with Fz, Vang and Pk, but has not been studied in vertebrates.
Human Molecular Genetics, 2009, Vol. 18, Review Issue 2 R123in Drosophila, as a genetic cascade involving the transmem-
brane receptor frizzled and the cytoplasmic protein dishev-
elled, but without a requirement for b-catenin (80–83). This
pathway is required to specify planar polarity in epithelia
including the wing and compound eye. In vertebrates, non-
canonical Wnt signalling is highly conserved, underpinning
tissue and cellular polarity during morphogenesis in systems
as diverse as gastrulation and the coordinated orientation of
stereociliary bundles in inner ear hair cells (84–90).
A potential role for PCP in NTDs ﬁrst came to light
following positional cloning of Vangl2 (the homologue of
Drosophila strabismus/Van gogh) in the loop-tail mouse
mutant which exhibits the severe NTD, craniorachischisis
(91,92). Subsequently, the same NTD phenotype was found
in other mouse mutants and targeted gene knockouts
(Table 2) almost all of which have been implicated biochemi-
cally in the PCP pathway (e.g. Celsr1, Dvl) or which interact
genetically with recognized PCP genes (e.g. Scrb, Ptk7)
(93,94). Interestingly, the double knockout for Smurf1 and
Smurf2 was recently found to display craniorachischisis and
other characteristic PCP defects. These genes encode ubiquitin
ligases whose targets include Prickle1 (Fig. 2), supporting the
crucial nature of PCP signalling for initiation of neural tube
closure (61).
In view of these ﬁndings in mice, PCP genes emerge as
excellent candidates for causation of craniorachischisis in
humans. Nevertheless, sequence analysis has so far failed to
identify mutations in human VANGL2 or its paralogue
VANGL1 in a group of patients with craniorachischisis
(95,96). Reports of other PCP gene analysis in similar patients
are awaited. Although craniorachischisis is the obvious NTD
phenotype for study, the VANGL genes have also been
analysed in patients with anencephaly and open and closed
spina biﬁda. No mutations were reported in VANGL2 (95,96)
but several highly conserved and unique, heterozygous mis-
sense variants were identiﬁed in VANGL1 in patients with
either myelomeningocele or closed spina biﬁda, as well as
caudal regression syndrome (96,97). To date a functional
effect has been demonstrated for one of these putative
mutations, where V239I (identiﬁed in caudal regression syn-
drome) results in loss of interaction between VANGL1 and
DVL proteins (96,).
Interestingly, loss of Vangl1 function is insufﬁcient to cause
NTDs in mice, although compound heterozygotes with Vangl2
(loop-tail) develop craniorachischisis (98). Nevertheless, there
is increasing evidence that PCP genes can contribute to NTDs
other than craniorachischisis (Table 2). For example, double
heterozygotes carrying both Vangl2 and Ptk7 develop spina
biﬁda (94) although Vangl2 double mutants with cordon-
bleu
C101 or Cthrc1 develop exencephaly (99,100). In contrast,
Vangl2:Scrb and Vangl2:Dvl3 double heterozygotes develop
craniorachischisis (101,102). It remains to be determined
why Vangl2 displays this variable phenotypic behaviour
when combined with different PCP and other mutants.
Hence, although non-canonical Wnt signalling has been
ﬁrmly linked with Closure 1 in mice, it is possible that
genes in this pathway play more diverse roles in human
neural tube closure.
CONCLUSIONS
The identiﬁcation of genetic risk factors for human NTDs
is complicated by the multiplicity of genes participating
Table 2. Genes of the planar cell polarity pathway—involvement in mouse NTDs
Gene Mutant/genotype Protein NTD phenotype References
Single gene effects
Vangl2 Loop-tail (Lp, Lp
m1Jus); Lp/Lp Transmembrane protein Craniorachischisis. Occasional spina
biﬁda in Lp/þ
(91,92,156,157)
Scrb1 Circle-tail; Crc/Crc Cytoplasmic polarity protein Craniorachischisis (93)
Celsr1 Crash; Crsh/Crsh Seven-pass transmembrane protein Craniorachischisis (158)
Spin-cycle; Scy/Scy Craniorachischisis
Ptk7 (CCK-4) Ptk7
mu/mu (truncating gene-trap allele) Transmembrane receptor tyrosine
kinase-like protein
Craniorachischisis (94)
Paralogous gene interactions
Dv11/2 Dvl1
2/2; Dvl2
2/2 Cytoplasmic signalling proteins Craniorachischisis (159)
Dvl2/3 Dv12
2/2; Dvl3
þ/2 (Dv12
2/2;3
2/2
die before E8.5)
Craniorachischisis (101)
Fz3/6 Fz3
2/2; Fz6
2/2 Transmembrane receptor protein Craniorachischisis (160)
Smurf1/2 Smurf1
2/2; Smurf2
2/2 Ubiquitin ligase No closure at E8.5 (61)
Smurf1
2/2;2
þ/2 or 1
þ/2;2
2/2 Spina biﬁda and/or exencephaly
Interactions between different genes
Vangl2/Scrb1 Lp/þ; Crc/þ See above Craniorachischisis (102)
Vangl2/Dvl3 Lp/þ;Dvl3
2/2 See above Craniorachischisis (101)
Lp/þ;Dvl3
þ/2 Craniorachishisis or exencephaly
Vangl2/Vangl1 Lp/þ; Vang1
gt/þ Transmembrane protein Craniorachischisis (98)
Vangl2/Ptk7 Lp/þ; Ptk7
þ/mu See above Spina biﬁda (94)
Vangl2/Wnt5a Lp/þ; Wnt5a
2/2 Secreted signalling protein Craniorachischisis (161)
Vangl2/Sfrp1,2,5 Lp/þ; Sfrp1
2/2; Sfrp2
2/2; Sfrp5
þ/2 Secreted Wnt antagonist Craniorachischsis (162)
Lp/þ; Sfrp1
2/2; Sfrp2
þ/2; Sfrp5
2/2 Spina biﬁda
Vangl2/Cthrc1 Lp/þ; Cthrc1
LacZ/LacZ Secreted glycoprotein, Wnt co-factor Exencephaly (100)
Vangl2/Grhl3 Lp/þ; Grhl3
ct/ct Transcription factor Severe spina biﬁda (163)
Vangl2/cobl Lp/þ; cobl
C101/C101 Actin nucleator Exencephaly (99)
R124 Human Molecular Genetics, 2009, Vol. 18, Review Issue 2in neurulation, and the importance of gene–environment
interactions. Sequence analysis of candidate genes implicated
from their role in mouse models has revealed putative
mutations in a few genes, but each in only a small number
of patients. Association studies of common polymorphic var-
iants, particularly related to folate one-carbon metabolism,
indicate risk factors such as MTHFR. However, no speciﬁc
folate-related gene has yet been implicated as a major deter-
minant of risk for NTDs. Large-scale studies will be required
to provide sufﬁcient statistical power to convincingly test
whether such variants are truly NTD susceptibility factors
(56,103). It will also be essential, to evaluate multiple
genes (folate-related and others) in the same individuals in
order to detect possible compounding effects of combinations
of risk alleles that, individually, might not be statistically
signiﬁcant (11,39). To date, very few studies have been
sufﬁciently large to overcome issues of multiple testing
bias in screening for gene–gene interactions (39,56,104).
Examination of speciﬁc hypotheses may be fruitful where
fewer NTD cases are available, particularly if combined
with stratiﬁed sample sets in which cases are sub-divided
on the basis of phenotype. For example, NTDs with abnormal
folate metabolism have enabled a combined analysis of
MTR and MTRR (105), and fetuses with craniorachischisis
provide a focus for determining the role of PCP genes.
Gene–environment interactions appear likely to contribute
to NTD predisposition, with examples including interactions
of MTHFR with multivitamin use (106), MTRR with
vitamin B12 (107) and PDGFRA with inositol and zinc (108).
One limitation of the association studies of multiple
folate-related candidate genes in NTDs is the predominant
focus on known polymorphisms. In future, it will be necessary
also to consider the possible existence of ‘private’ disease-
causing mutations. Moreover, the potential for deleterious gene
expression changes resulting from promoter mutations or copy
number variation has been addressed in relatively few studies
(10,108–110). Emerging technologies for high throughput
sequencing and analysis of genomic deletions and copy number
variations (111) offer the prospect, in the coming years, of
progress in identiﬁcation of candidate genes and screening for
novel mutations in human NTDs.
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